Sign in4 stories
The rare disease drugmaker reported Q2 2026 product sales of $37.6 million, added a hemangioma pipeline asset, and pushed guidance higher for the full year.
SEC filing
Eton Pharmaceuticals paid Auson Pharmaceuticals $3.0 million upfront for U.S. rights to ASN-001, a topical timolol gel, with an NDA targeted for the second half of 2027.
SEC filing
The appointment took effect July 31, 2026, elevating a longtime executive who has been with the company since 2017.
SEC filing
The company filed a Prior Approval Supplement seeking to lower KHINDIVI's approved age from five years, with a possible decision in the first half of 2027.
SEC filing